The Impact of the Microbiome on Resistance to Cancer Treatment with Chemotherapeutic Agents and Immunotherapy

Sevcikova, Aneta; Izoldova, Nikola; Stevurkova, Viola; Kasperová, Barbora Judita; Chovanec, Michal; Ciernikova, Sona; Mego, Michal

doi:10.3390/ijms23010488

Cited by 42 publications

(31 citation statements)

References 194 publications

(227 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mounting evidence from pre-clinical and clinical studies has documented the critical role of the human gut microbiome in the development of different types of cancer, including gastrointestinal and breast tumors, lymphomas, lung cancer, and many others [ 1 , 2 , 3 , 4 , 5 ]. In addition, the association between gut microbiota composition and cancer treatment efficacy highlights the potential of a microbiota-related approach in clinical oncology [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

Gut Microbiota–MicroRNA Interactions in Intestinal Homeostasis and Cancer Development

et al. 2022

Self Cite

View full text Add to dashboard Cite

Pre-clinical models and clinical studies highlight the significant impact of the host–microbiota relationship on cancer development and treatment, supporting the emerging trend for a microbiota-based approach in clinical oncology. Importantly, the presence of polymorphic microbes is considered one of the hallmarks of cancer. The epigenetic regulation of gene expression by microRNAs affects crucial biological processes, including proliferation, differentiation, metabolism, and cell death. Recent evidence has documented the existence of bidirectional gut microbiota–microRNA interactions that play a critical role in intestinal homeostasis. Importantly, alterations in microRNA-modulated gene expression are known to be associated with inflammatory responses and dysbiosis in gastrointestinal disorders. In this review, we summarize the current findings about miRNA expression in the intestine and focus on specific gut microbiota–miRNA interactions linked to intestinal homeostasis, the immune system, and cancer development. We discuss the potential clinical utility of fecal miRNA profiling as a diagnostic and prognostic tool in colorectal cancer, and demonstrate how the emerging trend of gut microbiota modulation, together with the use of personalized microRNA therapeutics, might bring improvements in outcomes for patients with gastrointestinal cancer in the era of precision medicine.

show abstract

Section: Introductionmentioning

confidence: 99%

Gut Microbiota–MicroRNA Interactions in Intestinal Homeostasis and Cancer Development

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…Multiple studies have shown that patients who did not receive antibiotics within 1-3 months before immunotherapy and had a rich fecal microbiota tended to respond better to ICIs [68]. Thus, consistent with the results of several clinical trials and conventional treatment, antibiotic exposure may reduce overall survival in patients receiving immunotherapy [69,70]. For example, in a prospective study, Pinato et al compared survival in 26 cancer patients who received antibiotics 30 days before ICIs with 151 who did not.…”

Section: The Limitations Of Fecal Microbiota Transplantation In Immun...mentioning

confidence: 64%

Cancer Immunotherapy: Fecal Microbiota Transplantation Brings Light

Zhang

Shi

et al. 2022

Curr. Treat. Options in Oncol.

View full text Add to dashboard Cite

Opinion statement Immunotherapy is revolutionizing tumor treatment by activating the immune response to tumors. Among them, immunotherapy represented by immune checkpoint inhibitors is considered to be a milestone in tumor treatment. It has revolutionized the management of advanced malignant tumors by activating T cells, promoting cytotoxic signaling pathways, and killing tumor cells, effectively improving the overall survival of patients. However, resistance to immunotherapy and immune-related adverse events remain challenges for immunotherapy. It has been demonstrated in previous studies that modulating intestinal microbiota can enhance immunotherapy response and reduce complications. Currently, the more mature method for microbiota regulation is fecal microbiota transplantation, which involves transfering a donor’s microbiome to the recipient in the form of capsules or fecal microbiota suspension to restore the richness of the recipient’s intestinal microbiota. In terms of cancer immunotherapy, fecal microbiota transplantation in patients who fail to respond to immune checkpoint inhibitors is expected to produce better prognosis for patients.

show abstract

“…The favorable clinical outcome during anti-PD1 therapy was linked to the presence of Akkermansia muciniphila , as well as to high diversity and abundance of Clostridiales/Ruminococcaceae / Faecalibacterium, Bifidobacterium longum , Collinsella aerofaciens , and Enterococcus faecium . Conversely, the poor responders harbored a low diversity and high abundance of Bacteroidales ( Robert et al, 2011 ; Sivan et al, 2015 ; Gopalakrishnan et al, 2018 ; Mao et al, 2021 ; Wong et al, 2021 ; Sevcikova et al, 2022 ).…”

Section: Gut Microbiota–antibiotics–antitumoral Agents Trialoguementioning

confidence: 99%

Common themes in antimicrobial and anticancer drug resistance

Chifiriuc

Filip

Constantin³

et al. 2022

Front. Microbiol.

View full text Add to dashboard Cite

Antimicrobial and anticancer drug resistance represent two of the main global challenges for the public health, requiring immediate practical solutions. In line with this, we need a better understanding of the origins of drug resistance in prokaryotic and eukaryotic cells and the evolutionary processes leading to the occurrence of adaptive phenotypes in response to the selective pressure of therapeutic agents. The purpose of this paper is to present some of the analogies between the antimicrobial and anticancer drug resistance. Antimicrobial and anticancer drugs share common targets and mechanisms of action as well as similar mechanisms of resistance (e.g., increased drug efflux, drug inactivation, target alteration, persister cells’ selection, protection of bacterial communities/malignant tissue by an extracellular matrix, etc.). Both individual and collective stress responses triggered by the chemotherapeutic agent involving complex intercellular communication processes, as well as with the surrounding microenvironment, will be considered. The common themes in antimicrobial and anticancer drug resistance recommend the utility of bacterial experimental models for unraveling the mechanisms that facilitate the evolution and adaptation of malignant cells to antineoplastic drugs.

show abstract

The Impact of the Microbiome on Resistance to Cancer Treatment with Chemotherapeutic Agents and Immunotherapy

Cited by 42 publications

References 194 publications

Gut Microbiota–MicroRNA Interactions in Intestinal Homeostasis and Cancer Development

Gut Microbiota–MicroRNA Interactions in Intestinal Homeostasis and Cancer Development

Cancer Immunotherapy: Fecal Microbiota Transplantation Brings Light

Common themes in antimicrobial and anticancer drug resistance

Contact Info

Product

Resources

About